# Stevanato Group

Type: Company (STVN)

Source: GetYourBrief — https://getyourbrief.com/entity/stevanato-group
Canonical HTML page: https://getyourbrief.com/entity/stevanato-group

## Recent coverage (5 stories, network-wide)

### Stevanato's FY 2026 Guidance Boosts Stock by 5%
2026-05-09 16:33:31 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Stevanato Group's FY 2026 earnings guidance highlights potential growth in the healthcare sector, influencing investor strategies amid market fluctuations. For finance professionals, this could signal opportunities in medtech stocks, with implications for portfolio diversification and risk assessment. Overall, it underscores the interplay between earnings forecasts and broader economic trends.
Full story: https://getfinancebrief.com/story/stevanato-fy2026-earnings-finance-impact

### Stem Achieves First Profitable Year as Software Pivot Drives Record Margins
2026-03-05 00:22:28 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 14

Stem (STEM) reached a critical financial milestone in Q4 2025, reporting its first full year of positive adjusted EBITDA and operating cash flow. The results highlight a successful strategic pivot toward high-margin software and services, which now account for over half of total revenue.
Full story: https://getfinancebrief.com/story/stem-q4-2025-earnings-software-pivot

### GLP-1 Surge Powers Stevanato Growth as Pulmonx Navigates Sales Restructuring
2026-03-05 00:20:39 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 14

Stevanato Group reported a 50% surge in GLP-1 related revenue for 2025, underscoring the massive impact of the weight-loss drug market on pharmaceutical supply chains. Conversely, medical device maker Pulmonx is undergoing a significant transition following a 50% turnover in its sales organization and a dip in U.S. quarterly revenue.
Full story: https://getbiobrief.com/story/stevanato-pulmonx-q4-2025-earnings-analysis

### Stem and Riskified Lead Shift Toward High-Margin Software and Services
2026-03-05 00:14:39 · Sector: retail · Sentiment: Positive · Impact: 6/10 · Sources: 14

A wave of Q4 2025 earnings reports highlights a sector-wide pivot toward high-margin software and recurring revenue models. Companies like Stem and Riskified are successfully transitioning away from low-margin hardware and transaction-heavy models to achieve record profitability and cash flow.
Full story: https://getretailbrief.com/story/stem-riskified-q4-2025-earnings-analysis

### GLP-1 Surge Drives Stevanato Growth as MedTech Sector Pivots to Efficiency
2026-03-05 00:14:04 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 14

Stevanato Group reported robust 2025 results fueled by a 50% surge in GLP-1 related revenue, while medical device maker Pulmonx initiated aggressive cost-cutting measures following a U.S. revenue decline. The divergence highlights a shifting healthcare landscape where specialized biopharma supply chains are outperforming traditional niche medical devices.
Full story: https://gethealthbrief.com/story/stevanato-pulmonx-earnings-glp1-trends-2025

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.